CLATAZEV Trademark

Trademark Overview


On Friday, February 19, 2021, a trademark application was filed for CLATAZEV with the United States Patent and Trademark Office. The USPTO has given the CLATAZEV trademark a serial number of 90536106. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, May 20, 2024. This trademark is owned by Bristol-Myers Squibb Company. The CLATAZEV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
clatazev

General Information


Serial Number90536106
Word MarkCLATAZEV
Filing DateFriday, February 19, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, May 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 12, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 21, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Friday, May 21, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 23, 2021NEW APPLICATION ENTERED
Tuesday, September 14, 2021ASSIGNED TO EXAMINER
Wednesday, September 15, 2021NON-FINAL ACTION WRITTEN
Wednesday, September 15, 2021NON-FINAL ACTION E-MAILED
Wednesday, September 15, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 4, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 4, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 4, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 8, 2022EXAMINERS AMENDMENT -WRITTEN
Tuesday, March 8, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, March 8, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, March 8, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, March 8, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 12, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 12, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 7, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, November 28, 2022SOU TEAS EXTENSION RECEIVED
Monday, November 28, 2022SOU EXTENSION 1 FILED
Monday, November 28, 2022SOU EXTENSION 1 GRANTED
Wednesday, November 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 30, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 30, 2023SOU EXTENSION 2 FILED
Tuesday, May 30, 2023SOU EXTENSION 2 GRANTED
Thursday, June 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, November 27, 2023SOU EXTENSION 3 FILED
Monday, November 27, 2023SOU EXTENSION 3 GRANTED
Wednesday, November 29, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 20, 2024SOU EXTENSION 4 FILED
Monday, May 20, 2024SOU EXTENSION 4 GRANTED
Monday, May 20, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 27, 2023SOU TEAS EXTENSION RECEIVED